---
title: >-
  Immunomodulators are Commonly Used as Concomitant Therapy with Vedolizumab or
  Ustekinumab: TARGET-IBD Real World Cohort.
description: >-
  Explore this publication on real-world evidence: Immunomodulators are Commonly
  Used as Concomitant Therapy with Vedolizumab or Ustekinumab: TARGET-IBD Real…
date: '2021-01-01'
category: Publications
tags:
  - DDW
  - Poster Presentation
  - Approval / Commercialization
  - Care
  - Gastroenterology
  - IBD
  - Health System Partner
canonical_url: >-
  https://www.pedestalhealth.com/resources/publications/ddw/immunomodulators-are-commonly-used-as-concomitant-therapy/
source: Pedestal Health
license: © 2026 Pedestal Health. All rights reserved.
slug: immunomodulators-are-commonly-used-as-concomitant-therapy
id: 3ylApiViWyy5uvZhz7ohYy
contentType: article
---

## Challenge

This is the DDW 2021 poster version of the immunomodulator combination therapy study (Row 5 manuscript). Earlier conference presentation characterizing the prevalence and predictors of immunomodulator use with vedolizumab and ustekinumab across the TARGET-IBD cohort.

## Solution

The TARGET-IBD registry was used to estimate combination therapy prevalence across vedolizumab-CD, ustekinumab-CD, and vedolizumab-UC patients, with descriptive comparison of combination versus monotherapy patient characteristics.

## Impact

Initial conference dissemination of combination therapy prevalence data at DDW 2021 establishes the real-world practice pattern baseline for non-TNF biologic combination use, informing prescriber education and the design of prospective combination therapy trials for vedolizumab and ustekinumab.

### [Julie M. Crawford](/people/julie-crawford/)